Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide an update with respect to its previously announced return of capital by way of an approximate $2,714,570 reduction in stated capital of the Company (the "Capital Reduction") and related distribution to the holders of common shares of the Company of a portion of the Company's cash in the amount of $0.03 per common share (the "Special Distribution"). F ...

Edwards Lifesciences Corporation (NYSE:EW) is one of the 14 Tech Stocks to Sell Now According to Ken Fisher. Edwards Lifesciences Corporation (EW) Welcomes Newly Updated ESC/EACTS Guidelines for Severe Aortic Stenosis (AS) In an announcement on August 29, 2025, Edwards Lifesciences Corporation (NYSE:EW) expressed its positive response to newly updated ESC/EACTS guidelines for severe aortic stenosis (AS), which recommend earlier treatment, including for asymptomatic patients, and lower the TAVR age thresh ...

East West Petroleum Shareholders Approve Capital Reduction and All Other Matters at the Annual and Special MeetingSeptember 05, 2025 4:30 PM EDT | Source: East West Petroleum Corp.Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that at the Annual and Special Meeting of Shareholders of the Company (the "Meeting") held on September 5, 2025, the shareholders re-elected Nick DeMare, Mark ...

Core Insights - The healthcare sector requires companies to develop unique technologies or products to maintain long-term success and withstand competition [1] - Identified companies with potential for sustained success include argenx SE, ICON plc, and Edwards Lifesciences Corp [2] Company Summaries Argenx SE - Argenx specializes in treatments for autoimmune diseases, particularly with its FDA-approved drug efgartigimod (VYVGART), which targets chronic autoimmune conditions like myasthenia gravis [2][3] - The company reported a 97% year-over-year increase in product sales, indicating strong market demand and growth potential [4] - All 21 analysts covering argenx have assigned a Buy rating, reflecting confidence in its future performance [4] ICON plc - ICON is a leading contract research organization (CRO) that provides outsourced development and commercialization services, particularly excelling in decentralized clinical trials [6][7] - Following its $12 billion acquisition of PRA Health Sciences, ICON has solidified its position as one of the largest CROs globally [6] - The company has demonstrated revenue resilience, with a commitment to shareholder value through $250 million in share repurchases and an authorization for up to $1 billion in additional buybacks [8] Edwards Lifesciences Corp - Edwards Lifesciences is a leader in medical devices for structural heart disease, particularly known for its transcatheter aortic valve replacement (TAVR) system [9][10] - The company has a strong market share in TAVR, with a favorable shift towards this minimally invasive procedure among surgeons [10] - Despite a slight decline in earnings per share year-over-year, analysts project over 12% earnings growth for the upcoming year, supported by robust R&D investments [11][12]

Core Insights - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Edwards Lifesciences Corporation and may file a class action on behalf of affected investors [1][2] Financial Performance - On July 24, 2024, Edwards reported second-quarter financial results for fiscal 2024 that were below expectations and reduced its full-year 2024 revenue guidance for its Transcatheter Aortic Valve Replacement (TAVR) platform [3] - The slowdown in TAVR was attributed to the growth of structural heart therapies, which impacted hospital workflows and led to underutilization of TAVR despite claims of a significantly undertreated patient population [3] - Edwards announced three acquisitions during the quarter aimed at enhancing treatments alternative to TAVR, indicating awareness of the decelerating growth of the TAVR platform [3] Stock Market Reaction - Following the disappointing disclosures, Edwards' stock price plummeted from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in a single trading day [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Edwards Lifesciences Corporation due to a class action complaint related to the company's fiduciary duties and misleading revenue expectations for its TAVR platform [1][2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Edwards who held shares between February 6, 2024, and July 24, 2024, following a class action complaint filed on December 13, 2024 [1]. - The law firm is encouraging affected investors to discuss their legal rights and options [1][5]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024, significantly lowering its revenue guidance for the TAVR platform for the full fiscal year [3]. - The company attributed the decline in TAVR performance to increased pressure on hospital workflows from the growth of other structural heart therapies, including its own TMTT [3]. - Following the announcement, Edwards' stock price plummeted from $86.95 to $59.70 per share, marking a decline of approximately 31.34% in one day [4]. Group 3: Company Strategy - During the second quarter, Edwards announced three acquisitions aimed at enhancing treatments alternative to TAVR, indicating a recognition of the potential slowdown in TAVR growth [3].

Core Viewpoint - The article discusses the regulatory challenges faced by Edwards Lifesciences in its acquisition of JenaValve Technology, highlighting the significance of the Trilogy system in the transcatheter aortic valve replacement (TAVR) market and the implications for the treatment of aortic regurgitation (AR) [2][10][14]. Group 1: Acquisition and Regulatory Challenges - On August 6, 2025, the FTC filed a lawsuit to block Edwards Lifesciences' acquisition of JenaValve Technology, citing concerns over reduced competition and potential negative impacts on innovation and patient choice [2][11]. - Edwards announced its intention to acquire JenaValve for $1.2 billion (approximately 8.6 billion RMB) in July 2024, aiming to enhance its TAVR product portfolio and address the long-standing treatment gap for AR [2][10]. - The FTC's action reflects a broader scrutiny from global regulatory bodies regarding market concentration in the structural heart disease sector, with the Austrian Federal Competition Authority also initiating a second-phase review of the transaction [12]. Group 2: Trilogy System and Market Implications - The Trilogy system, developed by JenaValve, represents a significant technological advancement in AR treatment, utilizing a self-expanding nitinol frame and a unique anchoring mechanism that does not rely on calcification [5][8]. - The system is designed to address the challenges faced by AR patients, particularly those with non-calcified annuli, and is expected to receive FDA approval by the end of 2025, potentially transforming the AR treatment landscape [8][13]. - Edwards aims to leverage its global sales network and clinical channels to accelerate the commercialization of Trilogy, which could provide a breakthrough treatment option for over 8 million severe AR patients in the U.S. alone [10][14]. Group 3: Financial Performance and Strategic Focus - Edwards Lifesciences has shown strong financial performance, with total revenue increasing by 11.9% year-over-year in Q2 2025, and TAVR sales growing by 8.9%, reflecting confidence in its core business despite regulatory uncertainties [13]. - The company is strategically focusing on expanding its structural heart portfolio, having sold its critical care business for $4.2 billion to BD, indicating a shift towards enhancing its capabilities in the structural heart market [10][13].

[Part I. Financial Information](index=4&type=section&id=Part%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Unaudited financial statements for June 30, 2025, report total assets of $13.49 billion, net sales of $2.94 billion, and net income of $691.2 million, reflecting discontinued operations Consolidated Balance Sheet Highlights (in millions) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $3,272.8 | $3,045.2 | | Total current assets | $6,577.2 | $6,285.4 | | Total assets | $13,488.7 | $13,055.3 | | **Liabilities & Equity** | | | | Total current liabilities | $1,404.7 | $1,505.2 | | Total liabilities | $2,882.2 | $2,992.4 | | Total stockholders' equity | $10,606.5 | $10,062.9 | Consolidated Statement of Operations Highlights (in millions, except EPS) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net sales | $2,944.9 | $2,699.3 | | Gross profit | $2,298.9 | $2,136.9 | | Operating income, net | $806.0 | $715.5 | | Net income attributable to Edwards | $691.2 | $718.2 | | Diluted EPS from continuing operations | $1.20 | $1.15 | Consolidated Statement of Cash Flows Highlights (in millions) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $570.6 | $318.0 | | Net cash (used in) provided by investing activities | $(86.8) | $187.9 | | Net cash used in financing activities | $(205.3) | $(34.9) | | Net increase in cash | $231.2 | $510.1 | - The historical results of the Critical Care product group, which was sold on September 3, 2024, and another non-core product group planned for sale, are now reported as discontinued operations, with all related notes primarily referring to continuing operations[30](index=30&type=chunk) [Note 4. Discontinued Operations](index=13&type=section&id=Note%204.%20Discontinued%20Operations) The company sold its Critical Care product group to BD, reclassifying it and another planned sale as discontinued operations, resulting in a net loss of $11.6 million for the six months ended June 30, 2025 - The company entered into a definitive agreement on June 3, 2024, to sell its Critical Care product group to BD, with the sale completed on September 3, 2024, and another non-core product group is also planned for sale in 2025[42](index=42&type=chunk) - In connection with the sale, Edwards entered into a Transition Services Agreement (TSA) to provide support services to BD for up to 36 months, recording an initial unfavorable contract liability of **$115.1 million**[45](index=45&type=chunk) Income from Discontinued Operations (in millions) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net sales | $33.3 | $531.2 | | Operating (loss) income, net | $(10.6) | $28.3 | | Net (loss) income | $(11.6) | $27.1 | [Note 6. Investments in Variable Interest Entities](index=18&type=section&id=Note%206.%20Investments%20in%20Variable%20Interest%20Entities) The company is involved with several VIEs, recognizing a **$47.1 million** impairment loss in June 2025 from not exercising an acquisition option, and continues to fund entities like JenaValve - In June 2025, the company decided not to exercise its option to acquire a medical device company, recognizing a **$47.1 million** loss on impairment[63](index=63&type=chunk) - The company has an agreement to acquire JenaValve Technology, Inc. and has advanced **$52.5 million** under a promissory note as of June 30, 2025[62](index=62&type=chunk) [Note 10. Accelerated Share Repurchase](index=27&type=section&id=Note%2010.%20Accelerated%20Share%20Repurchase) The company initiated a **$250 million** ASR in February 2025, repurchasing **3.5 million** shares at an average price of **$71.06** per share upon final settlement in July 2025 February 2025 ASR Agreement Summary (in millions, except per share data) | Amount Paid | Initial Shares Received | Final Settlement Date | Total Shares Received | Average Price per Share | | :--- | :--- | :--- | :--- | :--- | | $250.0 | 2.6 | July 2025 | 3.5 | $71.06 | [Note 11. Commitments and Contingencies](index=27&type=section&id=Note%2011.%20Commitments%20and%20Contingencies) The company faces several significant legal and regulatory matters, including patent infringement, a European Commission investigation, and a securities class action, with unpredictable outcomes - Aortic Innovations LLC filed a patent infringement lawsuit regarding the SAPIEN 3 Ultra product[91](index=91&type=chunk) - The European Commission is investigating the company's 'anti-copycat' policy and patent practices[92](index=92&type=chunk) - A putative securities class action was filed in October 2024 alleging false or misleading statements regarding business prospects, followed by related shareholder derivative actions[94](index=94&type=chunk)[95](index=95&type=chunk) [Note 14. Income Taxes](index=31&type=section&id=Note%2014.%20Income%20Taxes) The effective tax rate increased to **16.1%** from **8.8%** due to Pillar Two global minimum tax and lower share-based compensation benefits, with the company contesting a **$269.3 million** IRS deficiency notice - The effective tax rate for the six months ended June 30, 2025, increased to **16.1%** from **8.8%** in the same period of 2024[104](index=104&type=chunk) - The company expects the Pillar Two global minimum tax provisions to result in an additional tax expense of approximately **$50 million** in 2025[106](index=106&type=chunk) - The IRS issued a notice of deficiency for the 2015-2017 tax years, seeking an additional **$269.3 million** in tax related to transfer pricing, which the company plans to contest through the judicial process[112](index=112&type=chunk)[113](index=113&type=chunk) [Note 15. Segment Information](index=34&type=section&id=Note%2015.%20Segment%20Information) Total net sales reached **$2.94 billion**, with TAVR as the largest contributor at **$2.18 billion**, TMTT showing the highest growth, and the United States being the largest market at **$1.73 billion** Net Sales by Geographic Segment (in millions) | Region | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | United States | $1,728.6 | $1,588.5 | | Europe | $720.0 | $658.2 | | Japan | $177.1 | $172.5 | | Rest of World | $319.2 | $280.1 | | **Total** | **$2,944.9** | **$2,699.3** | Net Sales by Product Group (in millions) | Product Group | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Transcatheter Aortic Valve Replacement | $2,177.5 | $2,046.5 | | Transcatheter Mitral and Tricuspid Therapies | $249.7 | $155.9 | | Surgical Structural Heart | $517.7 | $496.9 | | **Total** | **$2,944.9** | **$2,699.3** | [Note 16. Subsequent Event](index=36&type=section&id=Note%2016.%20Subsequent%20Event) The FTC moved to block the proposed JenaValve acquisition on August 6, 2025, citing anticompetitive concerns, though the company intends to continue pursuing the acquisition - The U.S. Federal Trade Commission moved to block the proposed acquisition of JenaValve on August 6, 2025, due to anticompetitive concerns[127](index=127&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=37&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management reported 9.1% net sales growth to $2.9 billion, driven by TAVR and TMTT, with operating cash flow increasing to $570.6 million, amidst tax and regulatory challenges [Results of Operations](index=39&type=section&id=Results%20of%20Operations) Net sales grew **9.1%** to **$2.9 billion**, driven by TAVR and TMTT, with TMTT sales up **60.1%** to **$249.7 million**, while gross margin slightly decreased due to manufacturing expansion costs Net Sales Growth by Product Group (Six Months Ended June 30, 2025 vs 2024) | Product Group | 2025 Sales (M) | 2024 Sales (M) | Change (M) | % Change | | :--- | :--- | :--- | :--- | :--- | | TAVR | $2,177.5 | $2,046.5 | $131.0 | 6.4% | | TMTT | $249.7 | $155.9 | $93.8 | 60.1% | | Surgical Structural Heart | $517.7 | $496.9 | $20.8 | 4.2% | | **Total** | **$2,944.9** | **$2,699.3** | **$245.6** | **9.1%** | - TAVR sales growth was driven by the Edwards SAPIEN 3 Ultra RESILIA valve in the U.S. and Europe, and the company also received FDA approval for the SAPIEN 3 platform for severe aortic stenosis patients without symptoms in April 2025[144](index=144&type=chunk)[145](index=145&type=chunk) - TMTT sales growth was primarily due to higher sales of the PASCAL system and the launch of the EVOQUE tricuspid valve replacement system, and the company received CE Mark for the SAPIEN M3 mitral valve system in April 2025[148](index=148&type=chunk)[149](index=149&type=chunk) [Liquidity and Capital Resources](index=48&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held approximately **$4.0 billion** in cash and investments, with net cash from operations increasing to **$570.6 million**, and repurchased **3.4 million** shares for **$306.9 million** - Cash, cash equivalents, and short-term investments totaled approximately **$4.0 billion** as of June 30, 2025[180](index=180&type=chunk) - Net cash provided by operating activities increased by **$252.6 million** to **$570.6 million** for the first six months of 2025 compared to the same period in 2024[188](index=188&type=chunk) - During the first six months of 2025, the company repurchased **3.4 million** shares for **$306.9 million**, and as of June 30, 2025, **$1.1 billion** remained authorized for future repurchases[183](index=183&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=51&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes to market risk exposures, including interest rate, foreign currency, and credit risk, but highlights investment risk from $881.4 million in debt and $206.5 million in equity instruments - There have been no material changes to the company's primary market risks (interest rate, foreign currency, credit) since the 2024 year-end report[194](index=194&type=chunk) - The company is exposed to investment risk from its portfolio, which includes **$881.4 million** in debt securities and **$206.5 million** in equity instruments as of June 30, 2025[195](index=195&type=chunk) [Item 4. Controls and Procedures](index=51&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures are effective as of June 30, 2025, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that as of June 30, 2025, the company's disclosure controls and procedures are effective[196](index=196&type=chunk) - There were no changes in internal control over financial reporting during the quarter ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, internal controls[198](index=198&type=chunk) [Part II. Other Information](index=53&type=section&id=Part%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=53&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference the description of legal proceedings detailed in Note 11 of the financial statements - Information regarding legal proceedings is detailed in Part I, Item 1, Note 11 to the Consolidated Condensed Financial Statements[200](index=200&type=chunk) [Item 1A. Risk Factors](index=53&type=page&id=Item%201A.%20Risk%20Factors) No material changes to the company's risk factors have occurred since the filing of the 2024 Annual Report on Form 10-K - No material changes to the company's Risk Factors have occurred since the filing of the 2024 Annual Report on Form 10-K[201](index=201&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=53&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company did not purchase common stock under its regular repurchase program, but a $250 million ASR initiated in February 2025 concluded in July 2025, with 0.9 million shares delivered - As of June 30, 2025, the company had **$1.1 billion** remaining under its stock repurchase program authorized in August 2024[202](index=202&type=chunk) - The **$250.0 million** ASR agreement from February 2025 concluded on July 25, 2025, with the company receiving an additional **0.9 million** shares at settlement[203](index=203&type=chunk)

Core Viewpoint - The U.S. Federal Trade Commission (FTC) has moved to block JenaValve Technology's proposed acquisition by Edwards Lifesciences, which JenaValve intends to contest in court [1][2]. Company Overview - JenaValve Technology, Inc. is a medical device company focused on innovative transcatheter heart valve (THV) solutions for heart valve disease [3]. - The Trilogy THV System is designed for treating patients with symptomatic, severe aortic regurgitation (AR) and aortic stenosis, and has received CE Mark approval for dual-disease treatment capabilities in Europe [3]. - In the U.S., the Trilogy THV System is currently limited to investigational use only [3]. Company Locations and Backing - JenaValve is headquartered in Irvine, California, with additional locations in Leeds, United Kingdom, and Munich, Germany [4]. - The company is backed by several investment firms, including Bain Capital Life Sciences, Andera Partners, and Qatar Investment Authority (QIA) among others [4].

Regulatory Action - US FTC (美国联邦贸易委员会) 起诉阻止 Edwards Lifesciences 收购医疗设备制造商 JenaValve [1] Mergers and Acquisitions - Edwards Lifesciences 试图收购医疗设备制造商 JenaValve [1]